Skip to main content
. 2019 Nov 21;63(12):e01733-19. doi: 10.1128/AAC.01733-19

FIG 1.

FIG 1

Monthly sales of ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin in the United States. Sales data are presented as 3-month moving averages in U.S. dollars, beginning with the introduction of ceftazidime-avibactam to the market. The dip and subsequent rebound in sales of ceftazidime-avibactam in 2016 and 2017 corresponded to a nationwide supply shortage of the drug and its resolution.